VALNEVA SE SP.ADS/2 (F:AYJ0) — Market Cap & Net Worth
Market Cap & Net Worth: VALNEVA SE SP.ADS/2 (AYJ0)
VALNEVA SE SP.ADS/2 (F:AYJ0) has a market capitalization of $435.54 Million (€372.54 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #13271 globally and #1369 in its home market, demonstrating a -2.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VALNEVA SE SP.ADS/2's stock price €4.54 by its total outstanding shares 86876549 (86.88 Million). Analyse cash efficiency ratio of VALNEVA SE SP.ADS/2 to see how efficiently the company converts income to cash.
VALNEVA SE SP.ADS/2 Market Cap History: 2021 to 2026
VALNEVA SE SP.ADS/2's market capitalization history from 2021 to 2026. Data shows change from $5.02 Billion to $461.12 Million (-28.67% CAGR).
VALNEVA SE SP.ADS/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VALNEVA SE SP.ADS/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.25x
VALNEVA SE SP.ADS/2's market cap is 4.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.02 Billion | $348.08 Million | -$73.42 Million | 14.41x | N/A |
| 2022 | $1.25 Billion | $361.30 Million | -$143.28 Million | 3.47x | N/A |
| 2023 | $924.27 Million | $153.71 Million | -$101.43 Million | 6.01x | N/A |
| 2024 | $446.90 Million | $169.58 Million | -$12.25 Million | 2.64x | N/A |
| 2025 | $741.45 Million | $174.66 Million | -$115.19 Million | 4.25x | N/A |
Competitor Companies of AYJ0 by Market Capitalization
Companies near VALNEVA SE SP.ADS/2 in the global market cap rankings as of May 5, 2026.
Key companies related to VALNEVA SE SP.ADS/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
VALNEVA SE SP.ADS/2 Historical Marketcap From 2021 to 2026
Between 2021 and today, VALNEVA SE SP.ADS/2's market cap moved from $5.02 Billion to $ 461.12 Million, with a yearly change of -28.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €461.12 Million | -37.81% |
| 2025 | €741.45 Million | +65.91% |
| 2024 | €446.90 Million | -51.65% |
| 2023 | €924.27 Million | -26.32% |
| 2022 | €1.25 Billion | -75.00% |
| 2021 | €5.02 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of VALNEVA SE SP.ADS/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $435.54 Million USD |
| MoneyControl | $435.54 Million USD |
| MarketWatch | $435.54 Million USD |
| marketcap.company | $435.54 Million USD |
| Reuters | $435.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more